MNPR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...

Stats
Šios dienos apimtis	57 703.00
Vidutinė apimtis	3.89M
Rinkos kapitalizacija	10.84M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-0.0900 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.190
ATR14	$0.00400 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Cittadine Andrew	Sell	8 952	Restricted Stock Units
2024-03-31	Cittadine Andrew	Buy	8 952	Common Stock
2024-03-31	Cittadine Andrew	Sell	3 098	Common Stock
2024-03-31	Tsuchimoto Kim R	Sell	9 956	Restricted Stock Units
2024-03-31	Tsuchimoto Kim R	Buy	9 956	Common Stock

INSIDER POWER
36.17
Last 100 transactions
Buy: 1 127 208 \| Sell: 341 037

Tūris Koreliacija

Ilgas: -0.17 (neutral)

Trumpas: -0.88 (strong negative)

Signal:(57.23) Neutral

Monopar Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LRMR	0.885
COGT	0.853
CFLT	0.823

10 Labiausiai neigiamai susiję koreliacijos
BLKB	-0.804

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Monopar Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.23
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.16
( neutral )

Monopar Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.610

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.610

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-0.830

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Monopar Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.